OutSMARTing Barriers

ICBI’s game-changing SMART Molecule Technology Platform is capable of delivering therapeutic drugs across the blood-brain barrier and into the central nervous system to treat neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease.

Bridging life-changing sciences into the brain.

ICBI’s proprietary In Vivo technologies deliver unprecedented live imaging of Parkinson’s disease lesions in the brains of Parkinson’s transgenic mice.

1
1

A breakthrough solution waiting to reach the world.

Our SMART Molecules are ready to be tested in human patients for clinical diagnosis of Alzheimer’s disease and Parkinson’s disease.

An incremental step towards the mass distribution of our technology involves generating large quantities of the SMART Molecules by employing cloning procedures following GMP regulations.

For more details on our Phase 1 clinical trials, we invite you to view our Investor Section page to find more materials and information on our current capital raise.

Learn More

Changing the course of Parkinson’s and Alzheimer’s disease.

ICBI is developing breakthrough sciences and therapeutic drugs to help treat the combined total of 30 million individuals around the world battling these diseases. Through the SMART Molecule Technology Platform, ICBI hopes to eradicate other neurodegenerative diseases such as Brain Cancer and other major diseases in other parts of the body.

Learn More About the SMART Platform

Crossing the Blood-Brain Barrier to transport therapeutic drugs to the Brain.

ICBI is developing biologics that specifically target pathologic proteins in the central nervous system, thereby offering clinical potential for early diagnosis, monitoring and treatment of Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases.

Learn More

Recent Milestones

Since the company’s inception in 2008, ICBI scientists have published and worked extensively to produce a body of work respected by many institutions across the world.

2012

  • Established BBB permeability of ICBI anti-Alzheimer’s molecule
  • Established BBB permeability of anti- Parkinson’s molecule
  • Demonstrated proof-of-concept in an animal model: BBB permeability and binding to pathological lesions in the brain of Alzheimer’s mice

2013

  • Awarded Grant from the Michael J. Fox Foundation
  • Developed α-Synuclein-SM to diagnose and modify Parkinson’s disease
  • Demonstrated proof-of-concept in an animal model: BBB permeability and binding to pathological lesions in the brain of Parkinson’s mice
  • Submitted third utility patent to the US Patent Office

2014

  • Submitted fourth utility patent to the US Patent Office
  • Unprecedented live imaging of Parkinson’s disease lesions in the brains of Parkinson’s mice
  • Demonstrated BBB uptake and studied pharmacology of α-Synuclein-SM in 72 mice at the Center of Molecular Imaging, Canada
  • Demonstrated Integrity of the BBB in Transgenic and Non-Transgenic Mice
  • Developed tracers for imaging alpha- synuclein in Parkinson’s disease
  • Developed two additional SMs for Alzheimer’s disease and one for Parkinson’s disease

2015

  • Awarded grant from the Michael J. Fox Foundation (MJFF)
  • 5th Patent application submitted to the US Patent Office
  • Launched collaboration with UC Irvine to study the pharmacodynamics of one of our SMART Molecules
  • SMART Molecules technology presented at the MJFF in November
  • Generated SMART Molecule for phosphorylated-tau to treat Alzheimer’s disease
  • Small Animal PET-Imaging Scanner (Genesys 4) from Sofi Bio established

A-Syn is known to be an important pharmaceutical target for Parkinson’s disease.

In 2013, scientists at the Michael J. Fox Foundation (MJFF) published a research report in the Journal of Parkinson’s Disease stating, “the ability to image alpha-synuclein deposition in the brain would be a game changing achievement for the Parkinson’s disease field”. ICBI has addressed this challenge.

Learn More

News

May 17, 2016 in Press Releases

Third Party Validation of BBB Permeability and Target Specificity of SMs by Dr. Eliezer Masliah, UCSD

L A JOLLA, Calif. – May 11, 2014 – On May 11, 2014, ICB International, Inc., ("ICBI"), announced confirmation of third-party validation provided by Dr. Eliezer Masliah of the University of California, San... Read More
May 17, 2016 in Press Releases

Michael J. Fox Foundation: 2013 Rapid Response Innovation Awards – ICBI to Receive Grant

L A JOLLA, Calif. – April 4, 2014 – On April 4, 2014, ICB International, Inc., ("ICBI"), announced confirmation of it’s grant received from the Michael J. Fox Foundation upon being selected... Read More
January 4, 2016 in Press Releases

Brain Imaging Tracer for Parkinson’s Disease

L A JOLLA, Calif. – April 11, 2014 – On On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like... Read More